SS-31

Elamipretide

A synthetic tetrapeptide studied for its interactions with cardiolipin and the inner mitochondrial membrane.

Class: Mitochondrial cardiolipin binder
Vial reference: 10 mg
Report available: Compound-linked · batch not supplied

View testing / COA Research solution calculator

Inner mitochondrial membrane / conceptual scientific illustration

Regulatory context

Forzinity (elamipretide) received FDA accelerated approval in September 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Continued approval may depend on confirmatory evidence. This approval does not cover the Cybertide 10 mg research vial. FDA source

01 / COMPOUND IDENTITY

What SS-31 is

SS-31, also known as elamipretide or MTP-131, is a four-amino-acid peptide investigated in mitochondrial biology. Cardiolipin is a phospholipid enriched in the inner mitochondrial membrane, where energy-conversion processes occur.

Laboratory studies examine how SS-31 interacts with cardiolipin, membrane-associated proteins and mitochondrial function. These mechanisms do not, by themselves, establish a clinical benefit. Mechanistic study

Peptide sequence: D-Arg–Dmt–Lys–Phe–NH₂
Dmt: 2,6-dimethyltyrosine
Product distinction: Forzinity is a specific approved formulation; research material is not interchangeable with it.
Reviewed: September 12, 2026

02 / EVIDENCE LANDSCAPE

Research areas, with their limits

Separate biological mechanisms from findings in specific patient populations.

MECHANISTIC / PRECLINICAL

Cardiolipin & mitochondrial membranes

Cell, biochemical and animal work explores cardiolipin interactions, cytochrome c activity and mitochondrial bioenergetics. These results support research hypotheses, not general wellness claims.

Read the study

SPECIFIC REGULATORY INDICATION

Barth syndrome

Forzinity’s accelerated approval concerns a defined population and muscle-strength endpoint. The label reports no superiority over placebo on the randomized trial’s primary walking-distance and fatigue endpoints; strength improvements were observed in the open-label extension.

Read the FDA clinical findings

RANDOMIZED CLINICAL TRIAL

Primary mitochondrial myopathy

MMPOWER-3 did not demonstrate improvement over placebo in its primary six-minute walk and fatigue outcomes at 24 weeks. Exploratory findings do not overturn these negative primary results.

Read MMPOWER-3

This evidence does not establish SS-31 as a general anti-aging, endurance, recovery or cognitive-enhancement treatment.

03 / LABORATORY PREPARATION

Research Solution Calculator

Calculate concentration and the compound amount in a defined laboratory sample.

Compound mass mg

Enter the compound amount used in your calculation. The example starts at 10 mg.

Final solution volume mL

Use the final total solution volume, not simply the volume of solvent added.

Sample volume µL

CALCULATED RESULTS

This sample contains: 0.333333 mg; 333.333 µg in 100 µL
Resulting concentration: 3.33333 mg/mL

Concentration = mass ÷ final volume
Amount per sample = concentration × sample volume

Arithmetic assumes complete dissolution and a homogeneous solution. Use product documentation and a validated laboratory method to establish solvent compatibility, stability and storage conditions. This tool does not specify a preparation protocol or establish material quality.

04 / ANALYTICAL DOCUMENTATION

Testing / COA

The submitted laboratory document and its traceability limits, presented together.

Janoshik Analytical

Compound-linked report · 10 mg sample

Laboratory task: #225604
Product lot / batch: Not supplied on the report
Analysis date: August 21, 2026
Submitted by: ZLZ Peptides
SS-31 content: 10.07 mg
Purity: 99.948%
Identity evidence: Report names elamipretide (SS-31) analysis; no separate identity-method result is shown.

The blank batch field prevents exact-lot attribution to a Cybertide vial. Sterility and endotoxin results are not included. Reported purity is not a measure of clinical safety.

Open original COA Full laboratory record

05 / EVIDENCE LIBRARY